Elsevier

Clinical Imaging

Volume 29, Issue 5, September–October 2005, Pages 307-312
Clinical Imaging

Original article
Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck

https://doi.org/10.1016/j.clinimag.2005.01.024Get rights and content

Abstract

Objective

The aim of this study was to investigate the value of dynamic contrast-enhanced magnetic resonance imaging (MRI) in the differentiation of posttreatment fibrosis from recurrent carcinoma, by comparing the dynamic contrast-enhancement characteristics of the lesions.

Materials and methods

Twenty-six patients with previously treated carcinoma of the head and neck are studied by conventional and dynamic contrast-enhanced MRI at least 6 months after treatment by radiotherapy and/or surgery. Patients are divided into tumor-positive or -negative groups according to the radiological and clinical follow-up and biopsy. Lesion enhancement ratios at each dynamic sequence are calculated.

Results

The tumor-positive group consisted of 11 patients, while the tumor-negative group included 15 patients. Between the two groups, lesion enhancement ratios are found to be significantly different (P<.05).

Conclusion

Dynamic contrast-enhanced MRI may be a valuable modality in the differentiation of recurrent tumor from posttreatment fibrotic changes of the head and neck.

Introduction

Magnetic resonance imaging (MRI) is a valuable modality in the diagnosis and follow-up of patients with head and neck carcinoma. The role of MRI for differentiating recurrent tumor from fibrosis after treatment of head and neck carcinoma was previously investigated [1], [2], [3], [4], [5]. Recurrent tumors were found to demonstrate higher signal intensity (SI) on T2-weighted images than fibrotic benign changes do. However, further studies have shown that nonneoplastic inflammation or edema may also be responsible for T2 hyperintersity and that this finding is nonspecific [3]. In some cases, the identification of a suspicious lesion is still a challenge.

Dynamic contrast-enhanced MRI is valuable for the differentiation of tumor recurrence and posttreatment fibrosis in regions such as the breast, pelvis, gastrointestinal and musculoskeletal system [6], [7], [8], [9], [10], [11]. To the best of our knowledge, there is no dynamic contrast-enhanced MRI study regarding such differentiation in the head and neck region. In this study, we aimed to compare the dynamic enhancement characteristics of benign fibrotic and recurrent tumoral lesions and, therefore, to investigate the value of dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrotic changes from recurrent carcinoma of the head and neck.

Section snippets

Materials and methods

Twenty-six patients aged 23–72 years (mean: 55 years), with a history of head and neck carcinoma and a radiologically detectable lesion at the site of treatment, were included in the study. All patients had received a curative treatment as radiotherapy and/or surgery. The numbers of patients are shown in Table 1 according to the type of treatment received and location of primary tumor. Patients who have received any type of treatment during the last 6 months were not included in the study, to

Results

The analysis of the images revealed mass lesion in 9 and asymmetrical soft tissue thickening in 17 primary lesion sites. All patients with a mass and four patients with progression in the size of the radiologic lesion underwent biopsy. Biopsy results were consistent with tumor in 11 and fibrosis in 2 of these 13 lesions, and these patients were included in the tumor-positive and -negative groups, respectively. The remaining 13 patients that had no mass and showed no change in asymmetry at the

Discussion

The early detection of tumor recurrence in cancer patients is crucial for better prognosis. After a successful radiation therapy, tumor tissue shows regression and fibrotic tissue takes the place of the tumor [2]. In addition, after surgery, the early development of granulation tissue at the surgical site turns out to be a fibrotic scar [12]. Such benign reactions to treatment may mimic tumor both in physical and radiological examinations; therefore, the differentiation of tumor from fibrotic

References (18)

There are more references available in the full text version of this article.

Cited by (39)

  • Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer

    2018, Magnetic Resonance Imaging Clinics of North America
    Citation Excerpt :

    In semiquantitative analysis, Furukawa and colleagues47 showed that benign postradiation changes of the head and neck had a significantly longer time to peak (P = .024) and lower relative wash-out ratio (P = .007) than did recurrent tumors. Semiz Oysu and colleagues48 found significantly greater contrast uptake and enhancement ratio in posttreatment tumor-positive tissue compared with posttreatment fibrotic tissue (P<.05). Apart from DCE-MR imaging, Abdel Razek and colleagues49 investigated the use of DSC-MR imaging to differentiate benign from malignant posttreatment tissue in the head and neck.

  • State of the art MRI in head and neck cancer

    2018, Clinical Radiology
    Citation Excerpt :

    The DCE-MRI literature in the post-treatment setting has focused mainly on parameters derived from the TIC. In general, a gradual rise in the early phase and prolonged plateau is found in post-treatment change, while tumour shows early/rapid wash-in of contrast medium and relatively early wash-out.116–122 There is less research on quantitative DCE parameters using the kinetic models, although a few studies have shown smaller Ve,123 lower permeability (permeability surface area),124 and higher Kep125 in residual/recurrent tumour compared to post-treatment change.

  • Value of dynamic contrast enhanced magnetic resonance imaging in the differentiation between post-treatment changes and recurrent salivary gland tumors

    2016, Egyptian Journal of Radiology and Nuclear Medicine
    Citation Excerpt :

    Dynamic contrast enhanced imaging (DCE-MRI) produces information about the vascularity of cancers and has the potential to be used to detect and characterize tumors, and evaluate treatment response (15,16). Different studies demonstrated that dynamic contrast enhanced MRI is valuable for the differentiation of tumor recurrence and post-treatment fibrosis in different regions such as breast, pelvis, musculoskeletal system and in the head and neck regions (2,17). In this study we investigated the utility of DCE-MRI for the differentiation of recurrent malignant salivary gland tumors from post-treatment changes using two different analytical methods (the semiquantitative and the quantitative methods).

View all citing articles on Scopus
View full text